![Assessment of potentially reusable edible wild plant and mushroom gathering sites in eastern Fukushima based on external radiation dose - ScienceDirect Assessment of potentially reusable edible wild plant and mushroom gathering sites in eastern Fukushima based on external radiation dose - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0265931X20307116-fx1.jpg)
Assessment of potentially reusable edible wild plant and mushroom gathering sites in eastern Fukushima based on external radiation dose - ScienceDirect
![Predicting late radiation-induced xerostomia with parotid gland PET biomarkers and dose metrics - Radiotherapy and Oncology Predicting late radiation-induced xerostomia with parotid gland PET biomarkers and dose metrics - Radiotherapy and Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/38c68d65-ba33-47a3-8d4b-d7e17a9909e7/gr2_lrg.jpg)
Predicting late radiation-induced xerostomia with parotid gland PET biomarkers and dose metrics - Radiotherapy and Oncology
![G Live on Twitter: "Vaccinations Update: 18-39 yr olds can walk-in & get the Pfizer vaccine @GLiveGuildford until 7pm today. Pfizer also available for 18-39 yr olds on Fri 8am-7pm & Sat G Live on Twitter: "Vaccinations Update: 18-39 yr olds can walk-in & get the Pfizer vaccine @GLiveGuildford until 7pm today. Pfizer also available for 18-39 yr olds on Fri 8am-7pm & Sat](https://pbs.twimg.com/media/E5neQ-MWYAMA0lX.jpg)
G Live on Twitter: "Vaccinations Update: 18-39 yr olds can walk-in & get the Pfizer vaccine @GLiveGuildford until 7pm today. Pfizer also available for 18-39 yr olds on Fri 8am-7pm & Sat
![Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/f3be98d8-d68c-4273-a286-fc9e5079f0d6/gr1.jpg)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet
![Hindustan Times al Twitter: "The DCGI approved Biological E's coronavirus vaccine #Corbevax as a heterologous #COVID19 booster dose (also known as precaution shot) for all adults. Read more here: https://t.co/1incjIfkJm https://t.co/OU0e4xGUnK" / Hindustan Times al Twitter: "The DCGI approved Biological E's coronavirus vaccine #Corbevax as a heterologous #COVID19 booster dose (also known as precaution shot) for all adults. Read more here: https://t.co/1incjIfkJm https://t.co/OU0e4xGUnK" /](https://pbs.twimg.com/media/FUZ_6NyaMAAMrX1.jpg)
Hindustan Times al Twitter: "The DCGI approved Biological E's coronavirus vaccine #Corbevax as a heterologous #COVID19 booster dose (also known as precaution shot) for all adults. Read more here: https://t.co/1incjIfkJm https://t.co/OU0e4xGUnK" /
![Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded,](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/994abe4d-01fd-4a3c-9a37-fca8ec3521f2/gr1.gif)
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded,
![Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-020-01179-4/MediaObjects/41591_2020_1179_Fig1_HTML.png)
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine
Deep Learning–based Reconstruction for Lower-Dose Pediatric CT: Technical Principles, Image Characteristics, and Clinical Impl
![Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial - Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4f63598f-c60b-45d0-a83a-80252b2ff690/gr1.gif)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Dose-related effect of trisodium nitrilotriacetate monohydrate on renal tumorigenesis initiated with N-ethyl-N-hydroxyethyl- nit
![Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/db5c63dc-ee49-4b78-b05c-e93ffa8229af/gr1_lrg.jpg)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet
![Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial - Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial -](https://ars.els-cdn.com/content/image/1-s2.0-S2352301821001570-gr4.jpg)
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial -
![Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) - The Lancet Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c16a5f40-2895-426c-bada-3e4220ffec3f/gr1.gif)
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) - The Lancet
Deep Learning–based Reconstruction for Lower-Dose Pediatric CT: Technical Principles, Image Characteristics, and Clinical Impl
![Highly pathogenic avian influenza virus H5N1 controls type I IFN induction in chicken macrophage HD-11 cells: a polygenic trait that involves NS1 and the polymerase complex | Virology Journal | Full Text Highly pathogenic avian influenza virus H5N1 controls type I IFN induction in chicken macrophage HD-11 cells: a polygenic trait that involves NS1 and the polymerase complex | Virology Journal | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1743-422X-9-7/MediaObjects/12985_2011_Article_1674_Fig1_HTML.jpg)
Highly pathogenic avian influenza virus H5N1 controls type I IFN induction in chicken macrophage HD-11 cells: a polygenic trait that involves NS1 and the polymerase complex | Virology Journal | Full Text
![Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. - Journal Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. - Journal](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/cfd7c16d-2bb8-419e-9640-3161472c49da/gr1_lrg.jpg)
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. - Journal
![Technetium-99m-HMPAO, Technetium-99m-ECD and Iodine-123-IMP Cerebral Blood Flow Measurements with Pharmacological Interventions in Primates | Journal of Nuclear Medicine Technetium-99m-HMPAO, Technetium-99m-ECD and Iodine-123-IMP Cerebral Blood Flow Measurements with Pharmacological Interventions in Primates | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/38/12/1897.extract.jpg)